Optimmune Ophthalmic Ointment

0.2% Cyclosporine

Optimmune Ophthalmic Ointment For Dogs is indicated for management of chronic dry eye or keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK). Optimmune is easy to administer and helps to quickly relieve eye irritation due to dry eyes. Optimmune Ointment contains cyclosporine which increases tear production. It is not a cure for dry eye, but rather an effective treatment.

Dosage and Administration: Remove debris with suitable nonirritating solutions. Apply a 1/4 inch strip of ointment to the affected eye(s) every 12 hours. The ointment may be placed directly on the cornea or into the conjunctival sac.

It is recommended that dogs exhibiting chronic recurring conjunctivitis be tested for adequate tear production to determine if they are suffering from early stages of chronic KCS.

For best results in treating KCS, cyclosporine ophthalmic ointment should be administered early in the course of the disease before irreversible damage to the lacrimal tissue, or dense corneal scarring or pigmentation occurs.

Dogs afflicted with KCS or CSK will most likely require lifelong consistent therapy (see EFFICACY section). For CSK, because environmental factors such as ultraviolet (UV) radiation are implicated in the pathogenesis, clinical signs may subside in the winter months when light intensity is reduced or if the dog is moved to a lower altitude, or indoors, and thus exposed to less UV radiation.¹

In cases refractory to cyclosporine, the diagnosis should be re-evaluated and a different course of therapy considered. Periodic reassessment of the need for OPTIMMUNE Ophthalmic Ointment therapy is recommended.

Active Ingredient: Each gram of OPTIMMUNE Ophthalmic Ointment contains 2 mg of cyclosporine.

MODE OF ACTION: When applied ophthalmically, cyclosporine is believed to act as a local immunomodulator of diseases suspected to be immune-mediated such as keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK). In the management of KCS, the mechanism by which cyclosporine causes an increase in lacrimation is poorly understood. Clinical improvement in cases of KCS is not necessarily dependent on an increase in aqueous tear production (as measured by the Schirmer Tear Test [STT]).

PRECAUTIONS: The clinical effects of OPTIMMUNE Ophthalmic Ointment have not been determined in dogs with KCS due to the following conditions: congenital alacrima, sulfonamide usage, canine distemper virus, metabolic disease, surgical removal of the third eyelid gland, and facial nerve paralysis with loss of the palpebral reflex. Some of the underlying conditions which may lead to KCS can be either transient (eg, facial nerve trauma) or correctable with appropriate treatment. Consequently, recovery from clinical signs attributed to KCS may be observed and treatment options may need reconsideration.

When switching to cyclosporine from another therapeutic agent (eg, frequent application of an artificial tear preparation) for KCS or CSK, it should be kept in mind that clinical efficacy is not necessarily apparent immediately after initiation of OPTIMMUNE Ophthalmic Ointment therapy. Several days to a few weeks may be required before the clinical effects are of OPTIMMUNE Ophthalmic Ointment are of sufficient magnitude such that a previously initiated therapy can be safely withdrawn. Abrupt cessation of a therapeutic agent immediately upon initiation of OPTIMMUNE Ophthalmic Ointment therapy can result in rapid clinical relapse which may be erroneously interpreted as an adverse reaction to the OPTIMMUNE Ophthalmic Ointment.

The safety of OPTIMMUNE Ophthalmic Ointment has not been determined in cases of preexisting viral or fungal ocular infections. It is recommended that in such cases, OPTIMMUNE Ophthalmic Ointment therapy be delayed until the fungal/viral ocular infection has been successfully treated.

The safety of OPTIMMUNE Ophthalmic Ointment in puppies, pregnant bitches, or dogs used for breeding has not been determined.

ADVERSE REACTIONS: In the KCS clinical field trial, there were 20 adverse reactions reported out of 132 cases enrolled. This corresponds to an adverse reaction rate of 12.9% (13 of 101 cases) for OPTIMMUNE Ophthalmic Ointment treated dogs and 22.6% (7 of 31) for placebo treated dogs. The reactions described were primarily ocular and periocular inflammatory reactions. These were likely a function of therapy being unable to fully control the keratoconjunctivitis, rather than a true adverse reaction. Similarly, in the CSK trial, of 36 cases evaluated for safety, adverse reactions were noted in 2 animals (5.6%). One involved transient hyperemia, epiphora, and mild discomfort of the eye. The other involved periocular/palpebral inflammation and mild alopecia.

On rare occasion, instillation of OPTIMMUNE Ophthalmic Ointment may be associated with local irritation as manifested by periocular redness, lid spasm, and excessive rubbing. As the eyes of dogs with KCS often demonstrate considerable inflammation, it will be difficult to determine whether this local irritation constitutes a hypersensitivity to OPTIMMUNE Ophthalmic Ointment. If this ocular irritation persists beyond 7 days, hypersensitivity to a component of OPTIMMUNE Ophthalmic Ointment should be suspected and therapeutic options reassessed.